Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors

Bone Marrow Transplantation

Volumn 21, Issue SUPPL. 3, 1998, Pages

  Ordemann, R ^a   Holig K ^a   Wagner, K ^b   Rautenberg, U ^a   Bornhauser M ^a   Kroschinsky, F ^a   Schafer J ^a   Schuler, U ^a   Ehninger, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DKMS German Bone Marrow Donor Center   (Germany)

Author keywords

Bone marrow harvesting; PBSC mobilisation; Unrelated donors

Indexed keywords

ANALGESIC AGENT; HEMOGLOBIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APHERESIS; BONE MARROW CELL; BONE PAIN; CELL SELECTION; CLINICAL TRIAL; CONFERENCE PAPER; FATIGUE; FEASIBILITY STUDY; FEMALE; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE COUNT; MALE; NAUSEA; NORMAL HUMAN; PARESTHESIA; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SWEAT; THORAX PAIN; THROMBOCYTE COUNT; VERTIGO; VOMITING;

ADULT; BLOOD DONORS; BONE MARROW; BONE MARROW TRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 2642614495     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Kessinger A, Smith DM, Strandjord SE et al. Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643-646.
2. Körbeling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lym- phoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
3. Schmitz N, Dreger P, Suttor M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
4. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic PBSC mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
5. Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity and laboratory effects of granulocyte colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996; 36: 590-595.
6. Berdel WE, Danhauser-Riedl S, Oberberg D, Zafferani M. Effects of hematopoietic growth factors on malignant nonhematopoietic cells. Semin Oncol 1992; 19 (Suppl. 4): 41-45.
7. Brugger W, Brass KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
8. Baer MR, Bernstein SH, Brunetto VL et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood 1996; 87: 1484-1494.
9. Buckner CD, Clift RA, Sanders JE et al. Marrow harvesting from normal donors. Blood 1984; 64: 630-634.
10. Stroncek DF, Holland PV, Bartch G et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood 1993; 81: 1940-1946.
11. Bortin MM, Buckner CD. Major complications of marrow harvesting for transplantation. Exp Hematol 1983; 11: 916-921.